Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Lilly PharmaceuticalCompany
• Treatments: Ixekizumab

Criteria

Inclusion Criteria:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• diagnosis of idiopathic subglottic stenosis

Exclusion Criteria:

• History of active or latent tuberculosis infection

• History of inflammatory bowel disease

• Pregnancy or lactation

• Known allergic reactions to study drug

• Disease involving the vocal cords